Beyond ASH

Selina Luger, MD, FRCPC
top banner

Beyond ASH

Sagar Lonial, MD, FACP

12:29

Recently Presented Data of Clinical Trials in Patients with MM #BeyondASH21

Beyond ASH

Susan O'Brien, MD

19:51

; Recently Presented Data of Clinical Trials in Patients with CLL #BeyondASH21

Beyond ASH

Sonali Smith, MD, FASCO

18:18

Best Practices in Treating Aggressive Lymphomas #BeyondASH21

Beyond ASH

Nitin Jain, MD

13:11

Best Strategies for Incorporating Novel Agents, Combinations, and Sequencing of Agents/Regimens in the R/R Setting #BeyondASH21

Beyond ASH

Ruben Mesa, MD, FACP

14:27

Selection and Sequencing of JAK Inhibitors and Other Emerging Agents for MPNs #BeyondASH21

Beyond ASH

Nina Shah, MD

16:17

What Are the Latest Approaches for Using CAR T-cell Therapy for Hematologic Malignancies? #BeyondASH21

Beyond ASH

Kenneth Anderson, MD

13:23

Integrating Targeted Therapies for Relapsed/Refractory MM Into Practice #BeyondASH21

Beyond ASH

Michael Savona, MD

14:52

Recently Presented Data of Clinical Trials in Patients with MDS/MPNs #BeyondASH21

Beyond ASH

Eunice Wang, MD

14:20

How to Incorporate Emerging Novel Agents and Combinations in the R/R Setting for AML and ALL #BeyondASH21